医学
指南
梅德林
重症监护医学
疾病管理
冠状动脉疾病
疾病
内科学
医疗保健
观察研究
物理疗法
病理
帕金森病
政治学
法学
经济
经济增长
作者
Salim S. Virani,L. Kristin Newby,Suzanne V. Arnold,Vera Bittner,LaPrincess C. Brewer,Susan Halli Demeter,Dave L. Dixon,William F. Fearon,Beverly Hess,Heather M. Johnson,Dhruv S. Kazi,Dhaval Kolte,Dharam J. Kumbhani,Jim LoFaso,Dhruv Mahtta,Daniel B. Mark,Margo Minissian,Ann Marie Návar,Amit R. Patel,Mariann R. Piano
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2023-07-20
卷期号:148 (9)
被引量:519
标识
DOI:10.1161/cir.0000000000001168
摘要
AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since the “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease” and the corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.” METHODS: A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost–value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
科研通智能强力驱动
Strongly Powered by AbleSci AI